Clinical and Translational Science Award

临床和转化科学奖

基本信息

  • 批准号:
    10349079
  • 负责人:
  • 金额:
    $ 1012.1万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-07-01 至 2026-05-31
  • 项目状态:
    未结题

项目摘要

Contact PD/PI: Reilly, Muredach P OVERALL: PROJECT SUMMARY/ABSTRACT Our mission is to improve the health of our patients and communities both locally and nationally through innovations in clinical and translational research. Our strategic vision is to catalyze all phases of clinical and translational science (T0-T4), synergize with our partners and stakeholders, and integrate activities within our hub and across the national Clinical and Translational Science Award (CTSA) Program. To achieve this vision, we will build on our strong established track-record (e.g., in precision medicine), our plans to tackle important public-health challenges (e.g., COVID-19 pandemic, the opioid crisis) and to address critical barriers (e.g., innovation in use of electronic health records for research, clinical trial designs) as we embrace the CTSA Program priorities designated in PAR-18-940. Our vision is to transform the health and wellbeing of our communities in New York City, the nation and the world. To achieve this, we deploy our programs and resources to develop, demonstrate and disseminate innovations in clinical and translational science across the full translational spectrum. As a comprehensive CTSA, we offer a broad array of support for trainees, scholars and investigators across our entire hub which includes Columbia University, the Columbia University Irving Medical Center, the New York Psychiatric Institute, and New York Presbyterian Hospital. At the same time, we move flexibly and deeply to address critical scientific or institutional opportunities as well as major public health needs and gaps. We achieve success by approaching our goals at multiple levels: a) Ongoing strategic planning including an annual retreat to review operations and identify gaps, needs and opportunities; b) Monthly cross- cutting “Theme” meetings to enable collaborative problem-solving in addressing gaps and opportunities; c) An innovative Evaluation and Continuous Improvement strategy using participatory management to integrate evaluation into program planning and execution; and d) A highly successful, innovative interdisciplinary training and workforce development program built on a foundation of team science. Central to our efforts to improve health and wellbeing at personal, community and national levels is our emphasis on strategic collaboration and dissemination. Thus, we seek to continuously create and refine innovations for an integrated research- and user- friendly translational research environment at our hub by: Harnessing partnerships across our entire hub; Transforming collaborations with our local communities, the campus health system and across New York State; And by accelerating bidirectional dissemination of innovative practices and learnings through collaborations with the CTSA Program network and beyond. Project Summary/Abstract Page 221 Contact PD/PI: Reilly, Muredach P Narrative The Clinical and Translational Science Award (CTSA) allows Columbia University to support novel programs whose goal is to speed the transition from scientific discoveries made in the laboratory toward new therapies. Building on our strong established track-record, we will tackle important challenges and critical barriers to research. We will facilitate the training of scholars from diverse backgrounds underrepresented in translational science who are knowledgeable about and available to focus on translational science later in their careers.
联系PD/PI:Reilly,Muredach P 总体:项目总结/摘要 我们的使命是通过以下方式改善当地和全国患者和社区的健康 临床和转化研究的创新。我们的战略愿景是促进临床和 转化科学(T0-T4),与我们的合作伙伴和利益相关者协同,并整合我们的活动 中心和整个国家临床和转化科学奖(CTSA)计划。为了实现这一愿景, 我们将建立在我们强大的既定记录(例如,在精准医学领域),我们计划解决重要问题 公共卫生挑战(例如,COVID-19大流行、阿片类药物危机)和解决关键障碍(例如, 创新使用电子健康记录的研究,临床试验设计),因为我们拥抱CTSA PAR-18-940中指定的计划优先级。我们的愿景是改变我们的健康和福祉, 在纽约市的社区,国家和世界。为了实现这一目标,我们部署了我们的计划和资源, 开发、展示和传播创新, 临床和转化科学 在整个 平移谱 作为一个全面的CTSA,我们为学员,学者和 我们整个中心的调查人员,包括哥伦比亚大学,哥伦比亚大学欧文医学院 中心,纽约精神病研究所和纽约长老会医院。与此同时, 灵活和深入地解决关键的科学或机构的机会,以及主要的公共卫生需求 和差距。我们通过在多个层面实现目标来取得成功:a)持续的战略规划 包括每年举行一次务虚会,以审查业务情况并查明差距、需求和机会; B)每月交叉审查, 减少“主题”会议,以便在处理差距和机会时能够合作解决问题; 创新的评价和持续改进战略,利用参与式管理, 项目规划和执行的评估;以及d)非常成功的创新跨学科培训 和劳动力发展计划建立在团队科学的基础上。我们努力改善 个人、社区和国家层面的健康和福祉是我们战略合作的重点, 传播。因此,我们寻求不断创造和完善创新,为综合研究-和用户- 在我们的枢纽友好的翻译研究环境:利用我们整个枢纽的合作伙伴关系; 改变与我们当地社区,校园卫生系统和整个纽约州的合作; 并通过与合作加速创新实践和学习的双向传播 CTSA计划网络及其他。 项目摘要/摘要第221页 联系PD/PI:Reilly,Muredach P 叙事 临床和转化科学奖(CTSA)允许哥伦比亚大学支持新的项目 其目标是加速从实验室中的科学发现向新疗法的过渡。 我们将在过去良好的业绩基础上,应对重大挑战和关键障碍, research.我们将促进来自不同背景的学者的培训, 科学谁是知识渊博,并可专注于转化科学在他们的职业生涯后期。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Muredach P Reilly其他文献

Single-cell multimodal profiling of monocytes reveals diverse phenotypes and alterations linked to cardiovascular disease risks
单核细胞的单细胞多模式分析揭示了与心血管疾病风险相关的多种表型和变化
  • DOI:
    10.1101/2024.02.18.580913
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Alexander C. Bashore;Chenyi Xue;Eunyoung Kim;Hanying Yan;Lucie Y. Zhu;Huize Pan;Michael D Kissner;Leila S Ross;Hanrui Zhang;Mingyao Li;Muredach P Reilly
  • 通讯作者:
    Muredach P Reilly
1008-184 The effects of pravastatin and atorvastatin on markers of oxidant stress in vivo
  • DOI:
    10.1016/s0735-1097(04)91877-3
  • 发表时间:
    2004-03-03
  • 期刊:
  • 影响因子:
  • 作者:
    Bonnie Ky;Megan L Wolfe;Anne Burke;Philippe O Szapary;Muredach P Reilly;Jennifer B Dykhouse;Leanne T Bloedon;Garret A FitzGerald;Daniel J Rader
  • 通讯作者:
    Daniel J Rader

Muredach P Reilly的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Muredach P Reilly', 18)}}的其他基金

Smooth muscle cell-derived cell fates and cellular interactions in atherosclerotic plaque stability in disease progression and regression.
平滑肌细胞衍生的细胞命运和细胞相互作用在疾病进展和消退中动脉粥样硬化斑块的稳定性。
  • 批准号:
    10567844
  • 财政年份:
    2023
  • 资助金额:
    $ 1012.1万
  • 项目类别:
Identification of smooth muscle cell genes causal in atherosclerotic plaque stability and cardiovascular disease risk
鉴定导致动脉粥样硬化斑块稳定性和心血管疾病风险的平滑肌细胞基因
  • 批准号:
    10720225
  • 财政年份:
    2023
  • 资助金额:
    $ 1012.1万
  • 项目类别:
Clinical and Translational Science Award
临床和转化科学奖
  • 批准号:
    10674531
  • 财政年份:
    2022
  • 资助金额:
    $ 1012.1万
  • 项目类别:
Human LincRNAs in Macrophage Biology and Related Cardiometabolic Diseases
巨噬细胞生物学和相关心脏代谢疾病中的人类 LincRNA
  • 批准号:
    9402855
  • 财政年份:
    2017
  • 资助金额:
    $ 1012.1万
  • 项目类别:
Human LincRNAs in Macrophage Biology and Related Cardiometabolic Diseases
巨噬细胞生物学和相关心脏代谢疾病中的人类 LincRNA
  • 批准号:
    9983136
  • 财政年份:
    2017
  • 资助金额:
    $ 1012.1万
  • 项目类别:
Human LincRNAs in Macrophage Biology and Related Cardiometabolic Diseases
巨噬细胞生物学和相关心脏代谢疾病中的人类 LincRNA
  • 批准号:
    9531432
  • 财政年份:
    2017
  • 资助金额:
    $ 1012.1万
  • 项目类别:
Clinical and Translational Science Award
临床和转化科学奖
  • 批准号:
    10439923
  • 财政年份:
    2016
  • 资助金额:
    $ 1012.1万
  • 项目类别:
Clinical and Translational Science Award
临床和转化科学奖
  • 批准号:
    9309130
  • 财政年份:
    2016
  • 资助金额:
    $ 1012.1万
  • 项目类别:
Clinical and Translational Science Award
临床和转化科学奖
  • 批准号:
    10199125
  • 财政年份:
    2016
  • 资助金额:
    $ 1012.1万
  • 项目类别:
Clinical and Translational Science Award
临床和转化科学奖
  • 批准号:
    9932779
  • 财政年份:
    2016
  • 资助金额:
    $ 1012.1万
  • 项目类别:

相似海外基金

Depopulating Holding Centers during the COVID-19 Pandemic
COVID-19 大流行期间收容中心的人口减少
  • 批准号:
    2413624
  • 财政年份:
    2024
  • 资助金额:
    $ 1012.1万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 1012.1万
  • 项目类别:
    Standard Grant
Return to work after the COVID-19 pandemic: a biopsychosocial perspective
COVID-19 大流行后重返工作岗位:生物心理社会视角
  • 批准号:
    24K16416
  • 财政年份:
    2024
  • 资助金额:
    $ 1012.1万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Leveraging 'Positive Deviance' to improve learning under COVID-19 pandemic. A randomized intervention in rural East Africa
利用“正偏差”改善 COVID-19 大流行期间的学习。
  • 批准号:
    23K20687
  • 财政年份:
    2024
  • 资助金额:
    $ 1012.1万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Impact of Different Learning Modalities on Science and Mathematics Teachers' Effectiveness and Retention during the COVID-19 Pandemic
COVID-19 大流行期间不同学习方式对科学和数学教师的有效性和保留率的影响
  • 批准号:
    2243392
  • 财政年份:
    2023
  • 资助金额:
    $ 1012.1万
  • 项目类别:
    Continuing Grant
Fact-finding survey of nursing diagnoses, nursing outcomes, and nursing interventions in medical institution and edcational institution under COVID-19 pandemic
COVID-19大流行背景下医疗机构和教育机构护理诊断、护理结果和护理干预的实况调查
  • 批准号:
    23K09822
  • 财政年份:
    2023
  • 资助金额:
    $ 1012.1万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Leveraging an Existing Longitudinal Observational Cohort to Understand the Impacts of Cannabis Legalization and the COVID-19 Pandemic on Alcohol and Cannabis Use in At-risk Young Adults
利用现有的纵向观察队列来了解大麻合法化和 COVID-19 大流行对高危年轻人酒精和大麻使用的影响
  • 批准号:
    478397
  • 财政年份:
    2023
  • 资助金额:
    $ 1012.1万
  • 项目类别:
    Operating Grants
Genomic Epidemiology of Methicillin-Resistant Staphylococcus aureus Infections Prior to and During the COVID-19 Pandemic
COVID-19 大流行之前和期间耐甲氧西林金黄色葡萄球菌感染的基因组流行病学
  • 批准号:
    494305
  • 财政年份:
    2023
  • 资助金额:
    $ 1012.1万
  • 项目类别:
    Operating Grants
Did business support measures during COVID-19 pandemic create Zombie firms?: Evidence from Post-pandemic corporate performance
COVID-19 大流行期间的企业支持措施是否创造了僵尸公司?:大流行后企业绩效的证据
  • 批准号:
    23K18808
  • 财政年份:
    2023
  • 资助金额:
    $ 1012.1万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Development of high-throughput SARS-CoV-2 qPCR and amplicon sequencing to track COVID-19 pandemic
开发高通量 SARS-CoV-2 qPCR 和扩增子测序来追踪 COVID-19 大流行
  • 批准号:
    23KF0036
  • 财政年份:
    2023
  • 资助金额:
    $ 1012.1万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了